ArticleDrugs2016
The Impact of Shortages on Medication Prices: Implications for Shortage Prevention.
Article in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The consequences of medicine shortages on healthcare utilization and care fragmentation.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Generics in Medicaid increased in price and shifted to larger manufacturers amid 2022-2023 amphetamine shortage.Health affairs scholar · 2026Article
- Experiences of Healthcare Providers and Households Facing Healthcare Costs in Eastern Kasai/DR Congo: A Qualitative Analysis.ClinicoEconomics and outcomes research : CEOR · 2026Article
- The association between drug shortages and prices across 74 countries: uncovering global access inequities.BMJ global health · 2025Article
- Comparison of generic drug prices in Korea and eight high-income countries across four therapeutic classes.PloS one · 2025Article
- Drug Shortages Prior to and During the COVID-19 Pandemic.JAMA network open · 2024Article
- The association between drug pricing and drug shortage in Saudi Arabia: a retrospective database analysis.Journal of pharmaceutical policy and practice · 2023Article
- The impact of drug shortages on drug prices: evidence from China.Frontiers in public health · 2023Article
- Price increase negotiations to address drug shortages in South Korea's national health insurance.Frontiers in pharmacology · 2023Article
- [Shortage of supply of drugs in Spain. A health problem].Atencion primaria · 2019Article
- Medicine Shortages: Gaps Between Countries and Global Perspectives.Frontiers in pharmacology · 2019Article
- Shortage of Albendazole and Its Consequences for Patients with Cystic Echinococcosis Treated at a Referral Center in Italy.The American journal of tropical medicine and hygiene · 2018Article
- Drug Shortages in Canada and Selected European Countries: A Cross-Sectional, Institution-Level Comparison.The Canadian journal of hospital pharmacyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication shortages are frequent and have clinical and financial ramifications; however, their effect on drug prices remains unknown.
objectiveTo examine price progression of medications affected by a shortage.
methodsWe collected prices of medications covered under Medicare Part B, reflective of general market prices, and data on clinically relevant shortages for the period 2005-16. We used linear mixed-effects models to examine the price growth of affected medications.
resultsShortage medications demonstrated a quarterly price growth of -0.5 % (95 % confidence interval [CI] -1.6, 0.6) in the period preceding a shortage, 4.3 % (95 % CI 3.6, 4.5) during a shortage, and 4.1 % (95 % CI 2.6, 5.5) in the post-shortage period. Medications not affected by a shortage had a quarterly price growth of 0.2 % (95 % CI -0.3, 0.6).
conclusionsMedication shortages are associated with price increases, and these increases are likely reactive to the low profitability of the affected medications and thus, proactive collaboration between the US Food and Drug Administration and industry can serve to identify low-profit drugs and evaluate measures to ensure continued production.
Indexed as
Identifiers
27770351What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.